Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from Forte Biosciences (FBRX).
Forte Biosciences, Inc. successfully conducted its 2024 annual stockholders meeting, resulting in the election of Class I directors and the ratification of KPMG LLP as the independent accounting firm for the upcoming fiscal year. Additionally, stockholders approved an amended Equity Incentive Plan and a reverse stock split of not less than 1-for-5 and not more than 1-for-30. The board finalized the reverse stock split at a 1-for-25 ratio, to be effective from August 28, 2024, with proportional adjustments to outstanding equity awards and future issuance plans. No fractional shares will be issued, with stockholders receiving cash compensation instead.
For a thorough assessment of FBRX stock, go to TipRanks’ Stock Analysis page.
